Parallel Advisors LLC Acquires 3,742 Shares of Novartis AG $NVS

Parallel Advisors LLC lifted its holdings in Novartis AG (NYSE:NVS) by 29.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,366 shares of the company’s stock after buying an additional 3,742 shares during the quarter. Parallel Advisors LLC’s holdings in Novartis were worth $2,500,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Massachusetts Financial Services Co. MA increased its position in Novartis by 14.4% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 113,737 shares of the company’s stock valued at $15,681,000 after buying an additional 14,352 shares in the last quarter. Concurrent Investment Advisors LLC boosted its holdings in Novartis by 36.6% in the fourth quarter. Concurrent Investment Advisors LLC now owns 14,815 shares of the company’s stock worth $2,043,000 after acquiring an additional 3,967 shares in the last quarter. Truist Financial Corp grew its stake in shares of Novartis by 6.6% in the fourth quarter. Truist Financial Corp now owns 887,296 shares of the company’s stock worth $122,332,000 after acquiring an additional 54,682 shares during the last quarter. Evergreen Capital Management LLC grew its stake in shares of Novartis by 68.2% in the fourth quarter. Evergreen Capital Management LLC now owns 47,245 shares of the company’s stock worth $6,514,000 after acquiring an additional 19,155 shares during the last quarter. Finally, Brighton Jones LLC increased its holdings in shares of Novartis by 76.5% during the fourth quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock valued at $599,000 after acquiring an additional 2,666 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors.

Trending Headlines about Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Zacks raised its FY2026 EPS estimate to $8.82 from $8.75, bringing the forecast close to the broader consensus estimate of $8.85. It also increased its Q2 2027 estimate to $2.52 from $2.45 and Q2 2028 to $2.71 from $2.65, suggesting some confidence in earnings growth in those periods. Novartis earnings estimate report
• Neutral Sentiment: Zacks projects Novartis EPS of $9.67 for FY2027 and $10.62 for FY2028. While these figures imply continued earnings expansion from the FY2026 forecast, the FY2028 projection was reduced from $10.91, limiting the positive impact of the longer-term growth outlook. Novartis earnings estimate report
• Negative Sentiment: Analysts lowered several estimates, including Q3 2026 EPS to $2.22 from $2.30, Q4 2026 to $2.20 from $2.23, Q1 2027 to $2.31 from $2.41, Q3 2027 to $2.44 from $2.49, and FY2027 to $9.67 from $9.73. The cuts point to weaker near- and medium-term earnings expectations and may weigh more heavily than the limited upgrades. Novartis earnings estimate report

Novartis Stock Down 0.1%

NVS stock opened at $154.26 on Friday. Novartis AG has a 1-year low of $114.38 and a 1-year high of $170.46. The business has a fifty day moving average price of $152.87 and a 200-day moving average price of $153.08. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67. The stock has a market capitalization of $294.35 billion, a P/E ratio of 23.27, a P/E/G ratio of 2.64 and a beta of 0.45.

Novartis (NYSE:NVS) last released its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.The company had revenue of $14.95 billion for the quarter. Equities analysts forecast that Novartis AG will post 8.86 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on NVS shares. Citigroup reaffirmed a “buy” rating on shares of Novartis in a research report on Wednesday, July 22nd. Weiss Ratings reissued a “buy (b)” rating on shares of Novartis in a research report on Friday, July 24th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $141.20.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.